Of note, the treatment of MSA mice with verdiperstat reduced MPO activity and ameliorated the disease phenotype [46], thus providing a strong rational for assessing the potential beneficial effect of verdipestat in a clinical trial (NCT03952806 or M‐STAR study). This evidence concerns the gene MPO and multiple system atrophy.